|
BYETTA
The FDA has become aware of 30 reports of acute pancreatitis in patients taking Byetta (exenatide), a drug used to treat adults with type 2 diabetes. An association between Byetta and acute pancreatitis is suspected in some of these cases. Patients are reporting severe pain and side effects. Both Eli Lilly and Amylin Pharmaceuticals, Inc. are updating the labeling for Byetta to include the increased risk of pancreatitis.
Healthcare professionals should be alert to the signs and symptoms of acute pancreatitis and instruct patients taking Byetta to seek prompt medical care if they experience unexplained, persistent, severe abdominal pain, which may or may not be accompanied by vomiting. If pancreatitis is suspected, Byetta should be discontinued. If pancreatitis is confirmed, Byetta should not be restarted unless an alternative etiology is identified.
BYETTA NEWS
The FDA has received thirty reports of acute pancreatitis (rapid-onset inflammation of the pancreas) in type 2 patients taking Byetta. Twenty-seven of the thirty patients had one or more risk factors for acute pancreatitis, such as gallstones or alcohol use. (Nov 05-07) DIABETES HEALTH: BYETTA
The US Food and Drug Administration (FDA) has announced that both Eli Lilly and Amylin Pharmaceuticals are updating the labeling for Byetta to include the increased risk of pancreatitis. (Nov-04-07) LAS: BYETTA
|
 |
|